Lilly ends Phase III development of gamma secretase inhibitor for Alzheimer's
This article was originally published in Scrip
Hopes for a therapy that slows or halts the progression of Alzheimer's disease have been dashed again after Lilly said that it would cease development of its gamma secretase inhibitor semagacestat, after an interim analysis from two ongoing pivotal Phase III studies showed it did not slow disease progression in those with mild-to-moderate disease.
You may also be interested in...
The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.